DOI: 10.36347/sjams.2017.v05i07.010

Pages: 2535-2537

Breast cancer is the most common cancer of women in the world. Its mortality has decreased considerably due to the progression of cancer treatments. Trastuzumab is advancement in oncology but its cardiac toxicity remains a limiting factor in its use. To determine the incidence of this cardiotoxicity and to define the predictive factors of its occurrence in adjuvant situation. Material and methods: prospective study of 100 patients treated for adjuvant breast cancer at the Mohammed VI University Hospital Center in Marrakech - Morocco. Predictive factors for the occurrence of cardiotoxicity were studied. 39 patients had cardio toxicity (36 asymptomatic cases and 3 symptomatic patients) with an absolute decrease of 4.2% (p <0.001). In multivariate analysis, a decreased left ventricular ejection fraction (LVEF) is the only significant risk factor (p <0.001). The associated treatments (antracyclines and radiotherapy) do not represent a predictive factor of cardiotoxicity in our series (p = 1 and p = 0.74 respectively).Cardiac tolerance to trastuzumab in our series appears comparable with data from the literature. A decreased initial LVEF is a predictor of cardiotoxicity to trastuzumab.